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Abstract
Background: Novel methods to aid identification of dogs with spontaneous Cushing's
syndrome are warranted to optimize case selection for diagnostics, avoid unneces-
sary testing, and ultimately aid decision-making for veterinarians.
Hypothesis/Objectives: To develop and internally validate a prediction tool for dogs
receiving a diagnosis of Cushing's syndrome using primary-care electronic health
records.
Animals: Three hundred and ninety-eight dogs diagnosed with Cushing's syndrome
and 541 noncase dogs, tested for but not diagnosed with Cushing's syndrome, from
a cohort of 905 544 dogs attending VetCompass participating practices.
Methods: A cross-sectional study design was performed. A prediction model was
developed using multivariable binary logistic regression taking the demography, pre-
senting clinical signs and some routine laboratory results into consideration. Predic-
tive performance of each model was assessed and internally validated through
bootstrap resampling. A novel clinical prediction tool was developed from the final
model.
Results: The final model included predictor variables sex, age, breed, polydipsia,
vomiting, potbelly/hepatomegaly, alopecia, pruritus, alkaline phosphatase, and urine
specific gravity. The model demonstrated good discrimination (area under the
receiver operating curve [AUROC] = 0.78 [95% CI = 0.75-0.81]; optimism-adjusted
AUROC = 0.76) and calibration (C-slope = 0.86). A tool was developed from the
model which calculates the predicted likelihood of a dog having Cushing's syndrome
from 0% (score = −13) to 96% (score = 10).
Conclusions and Clinical Importance: A tool to predict a diagnosis of Cushing's syn-
drome at the point of first suspicion in dogs was developed, with good predictive
Abbreviations: ALKP, alkaline phosphatase; ALT, aminotransferase; AUROC, area under the receiver operating curve; CITL, calibration-in-the-large; EHRs, electronic health records; EPV, events-
per-variable; IQR, interquartile range; LDDST, low dose dexamethasone suppression test; LRT, likelihood ratio test; UCCR, urine cortisol-creatinine ratio; USG, urine specific gravity; WHWT,
West Highland white terrier.
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performance. This tool can be used in practice to support decision-making and
increase confidence in diagnosis.
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1 | INTRODUCTION
Spontaneous Cushing's syndrome (or hyperadrenocorticism) is one of
the more common endocrine diseases in dogs with an estimated UK
prevalence of 0.28%.1,2 Cases of Cushing's syndrome typically show
varying combinations of polydipsia, polyuria, polyphagia, muscle atrophy,
hepatomegaly, dermatological changes, and laboratory changes.1,3-5 Spe-
cific diagnostic tests such as the adrenocorticotropic hormone (ACTH)
stimulation test and the low dose dexamethasone suppression test
(LDDST) are commonly used to increase confidence in the diagnosis of
Cushing's syndrome.1,6 However, there is no single highly accurate test,
making a confident diagnosis difficult.7-11 The ACTH stimulation test and
LDDST have low positive predictive values when used in a low preva-
lence setting, therefore their interpretation are reliant on a high prior
index of suspicion of disease and are impractical for disease screening.6,9
Other tests more suitable as screening tools, such as the urine cortisol-
creatinine ratio (UCCR), are not commonly used in primary-care practice
and are impacted by a high false positive rate with specificity estimates
ranging from 21% to 77%.1,10,12-14 Novel methods to aid the identifica-
tion of the highest risk dogs within the at-risk population are warranted
to increase confidence in diagnostic blood tests through an increase of
the positive predictive value, avoid unnecessary testing, and to generally
aid decision-making for primary-care practitioners. A timely and correct
diagnosis of Cushing's syndrome is important because of the reduced
quality-of-life in affected dogs and to ensure dogs are appropriately man-
aged while living with the disease.15
Although individual risk factors such as age, breed, and sex have
been associated with the diagnosis of Cushing's syndrome,1,2,16 the
cumulative risk and predictive value from combinations of results
from these risk factors for individual dogs are unknown. The previ-
ously reported explanatory regression models provide population level
inferences about the strength of a risk factor association in relation to
the causal hypothesis, but these are not directly applicable to the diag-
nosis of Cushing's syndrome in individual dogs by practitioners in practice.
Prediction models aimed at the individual level are increasingly being devel-
oped and utilized in human medicine to aid decision-making in clinical set-
tings.17 In a diagnostic setting, prediction models combine 2 or more risk
factors to estimate the probability that a certain disease is currently present
(or absent) in an individual.18 Regression and machine learning methods
have been used to develop clinical prediction models in humans with suffi-
ciently large datasets necessary to ensure accurate predictions for diseases
such as cardiovascular disease, dementia, and diabetes mellitus.19-21
Our study aimed to develop and internally validate a model to predict
dogs receiving a diagnosis of Cushing's syndrome using demographic,
presenting clinical signs and routine clinicopathologic data. From the
model, it was aimed to develop a corresponding tool which calculates the
predicted likelihood of a specific dog having Cushing's syndrome. This
tool could be readily applied by clinicians in practice to evaluate an indi-
vidual dog's risk of disease before confirmatory diagnostic testing, to
increase confidence in the diagnosis of Cushing's syndrome.
2 | MATERIALS AND METHODS
2.1 | Study population and predictors
Data were collected from the VetCompass programme, which collates
electronic health records (EHRs) from primary-care veterinary prac-
tices in the United Kingdom.22 Dogs in the VetCompass cohort were
required to have been under veterinary care in 2016 which was
defined as having (1) at least 1 EHR recorded during 2016 and/or
(2) at least 1 EHR recorded both in 2015 and 2017. Search terms were
applied to EHRs of these dogs to identify those where Cushing's syn-
drome was considered as a clinical diagnosis: “Cushing*, HAC, hyperadren*,
hyperA, trilos*, Vetory*.” All dogs eligible for inclusion in the analysis were
reviewed through manual revision of EHRs identified by the search terms.
The case definition required dogs to have (1) an initial diagnosis of Cus-
hing's syndrome recorded within the EHR between January 1, 2016 and
June 1, 2018 and (2) a record of a LDDST or ACTH stimulation test being
performed within the EHR before diagnosis. Dogs were excluded as a case
if (1) a subsequent revision of the diagnosis was made in the EHR, (2) a
diagnosis was made before their first health record, or (3) if cases were con-
sidered iatrogenic or had glucocorticoid administration in the 30 days
before first suspicion. A comparison reference population required dogs to
have (1) a recorded suspicion of Cushing's syndrome within the EHR
between January 1, 2016 and June 1, 2018 as identified by the search
terms, (2) subsequently had Cushing's syndrome ruled out after undergoing
at least a UCCR, LDDST, and/or an ACTH stimulation test, and (3) an alter-
native diagnosis made within the EHR. Dogs where Cushing's syndrome
continued to be suspected but the disease neither confirmed nor ruled out
during the time period from January 1, 2016 to June 1, 2018 were
excluded from the analysis. A random selection of eligible dogs was
included in analysis, based on a priori sample size calculations. Effective
sample size was estimated using events-per-variable (EPV), which is the
ratio of the number of predictor variables included in model development
relative to the number of events (number of dogs diagnosed with Cushing's
syndrome).23 An EPV of at least 10 is recommended and frequently cited
in the literature.24,25 An a priori sample size calculation estimated that
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between 260 and 520 cases were required if 26 predictor variables were
included in the modeling process, to ensure a sufficient EPV between
10 and 20. Ethics approval was provided by the Royal Veterinary College
Ethics and Welfare Committee (URN SR2018-1652). All analyses were car-
ried out using Stata 15 (Stata, College Station, Texas).
Predictor variables included from routinely collected data were
age, breed, bodyweight, sex, and neuter status. Breeds were catego-
rized according to a standardized breed list adapted from the VeNom
Coding Group system (Venom Coding Group 2019). Individual breeds
were specified if at least 20 dogs of that breed had been included for
analysis. All other purebreds were grouped into a “purebreed other”
category. Dogs classified as a breed-cross (eg, poodle X) or a designer
breed (eg, cockapoo) were classified into a “crossbreed” category. Sex
was categorized to include neuter status: female-entire, female-neu-
ter, male-entire, or male-neuter. Age at first suspicion (years) was cal-
culated by using the date of birth and date of first suspicion of
Cushing's syndrome. Bodyweight (kg) was the bodyweight value recorded
closest to the date of first suspicion.
Additional data were extracted manually from the EHRs of the
cases and noncases. Date of first suspicion was the earliest date with
evidence that Cushing's syndrome was being considered as a diagno-
sis. Clinical signs and laboratory measurements 1 week before and
1 week after the date of first suspicion were extracted. Animals with
no recorded information regarding clinical signs within this 2-week
period were excluded from the analysis. Individual clinical signs as evi-
dent in the EHRs were extracted as binary variables: “yes” or “no”
(either no information recorded or specifically recorded as not pre-
sent). Clinicopathologic data extracted included categorical variables
of alkaline phosphatase (ALKP) and alanine aminotransferase (ALT)
(recorded as “elevated,” “not elevated,” or “unknown”). Proteinuria
(based on a urine dipstick, including a trace recording or a urine
protein-creatinine ratio) was recorded as “present,” “not present,” or
“not recorded.” Urine specific gravity (USG) was recorded as “dilute”
(≤1.020), “not dilute” (>1.020), or “not recorded.” Continuous data for
recorded ALKP enzyme activities and USG measurements were also
extracted. Treatment data were extracted for insulin, l-thyroxine sup-
plementation, and antihypertensives (amlodipine, benazepril, enalapril,
or telmisartan).26 Additional clinical management data were extracted
to identify dogs that were hospitalized and had surgery for a cruciate
rupture in the previous 12 months before first suspicion.6,27 For
noncases, the final alternative diagnosis recorded in the EHR was also
extracted.
Data were examined before modeling to report descriptive statis-
tics for the predictor variables. Categorical data were presented show-
ing the counts and corresponding percentages. Quantitative data
were assessed graphically for normality; normally distributed data
were summarized using the mean (SD) and non-normally distributed
data using the median (interquartile range [IQR] and range). Potential
pairwise correlations between predictor variables were explored to
identify potential collinearity using correlation coefficients for contin-
uous predictors. Predictor variables were considered highly correlated
if r > 0.80.28 Associations between categorical variables were assessed
by chi-squared tests and were considered to be highly related if
P < .001 and were plausibly associated with each other.29 When pairs
of highly correlated predictor variables were identified, the variable
considered to be most complete within the data set and most clinically
relevant was selected for modeling.28 Variables with large amounts of
missing data (>65%) were excluded from further analysis, based on the
consensus of the authors.30,31 A separate “not recorded” category was
used to include missing data for variables with ≤65% missingness.
2.2 | Model development and internal validation
Multivariable binary logistic regression with 200 bootstrap samples
was used to develop and internally validate the diagnostic prediction
model for Cushing's syndrome in dogs.32,33 In each bootstrap sample,
dogs were randomly selected with replacement until a data set of the
same size was obtained, including approximately 63.2% of the dogs
from the study population.32 A backward stepwise model building
approach was used with sequential elimination of predictors with the
largest P value based on likelihood ratio tests (LRTs), within each
bootstrap sample (LRT P < .10).34,35 No univariable screening was
undertaken. Predictors which remained significant at the 10% level
were retained in the final model, to minimize the risk of rejecting pre-
dictor variables potentially important in future applications of the
tool.35
Internal validation assessed how well the model was likely to per-
form in an independent data set. Developed prediction models tend
to overfit the data and can be overly “optimistic” of their future per-
formance.33 Internal validation quantified the model optimism by:
(1) estimating optimism-adjusted performance measures and (2) adjusting
the model for overfitting by reducing the model coefficients toward the
null (shrinkage).23,33 The average difference between the performance
of the bootstrap samples (apparent performance) and the dogs not
included in the bootstrap samples calculated the optimism of the model
and estimated optimism-adjusted performance measures.36 Uniform
shrinkage to correct for model optimism was applied by multiplying the
optimism-adjusted calibration slope with the coefficients.21,33 The model
constant was reestimated based on the adjusted coefficients to maintain
overall model calibration.33
Continuous variables were assessed for linear associations with the
outcome using the LRT for departure from trend and LRT for extra-
linear effect. Nonlinear continuous predictors were modeled using lin-
ear splines.37,38 Potential confounding was assessed by reinserting
eliminated predictors into the developed model to assess the magni-
tude of changes in the model coefficients. A 20% change in the odds
ratio when the subsequent variable was added to the model was used
to identify potentially confounding variables.28 Potential interactions
between predictors were assessed using LRTs. The potential clustering
effect of the clinics included within the study was assessed by including
clinic ID as a random effect in a mixed effect model.
Performance of the model was assessed by examining the cali-
bration and discrimination.39 Calibration measures the agreement
between the observed outcomes and predictions. A calibration plot
compared the predictions within each bootstrap sample with the
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observed outcomes. The plot compares the mean observed propor-
tions of dogs with a diagnosis of Cushing's to the mean predicted
probabilities by deciles of predictions. Perfect predictions should lie
on the 45! line.40,41 Overall model calibration was calculated from the
mean calibration plot gradients (c-slope) and intercepts (calibration-in-
the-large [CITL]). The c-slope was used as the shrinkage factor to gain
the optimism-adjusted model coefficients. The c-slope is often lower
than 1 for models developed using relatively small data sets suggesting
that predictions are too extreme (ie, low predictions are too low, high
predictions are too high).39 CITL > 0 suggests that observed propor-
tions are higher than the predicted probabilities (predictions are sys-
tematically too low) and CITL < 0 suggests that predicted proportions
are higher than the observed proportions (systematically too high).39
Discrimination was assessed using the area under the receiver
operating characteristic curve (AUROC), with 95% confidence inter-
vals. The Brier score and Cragg-Uhler's (Nagelkerke) R2 assessed overall
model performance, a concept related to goodness-of-fit in explanatory
models.40,41 Brier score ranges from 0 to 1, with scores <0.25 indicating
better overall performance. Cragg and Uhler's R2 is a measure of
explained model variance and ranges from 0 to 1.40
2.3 | Prediction tool
A clinical prediction tool that estimates the probability of a dog receiv-
ing a diagnosis of Cushing's syndrome was developed based on the
function of the regression coefficients. To derive the points for the
predictive tool, the regression coefficients for each predictor variable
were used as weights which were divided by a common factor (the
smallest significant coefficient in the final model) and rounded to the
nearest integer.42 A dog's total score is calculated by additive combi-
nation of the points scored for each predictor.42,43 The predicted like-
lihood (p^ ) for each possible total score was calculated for ease of
reference in clinical practice by the following steps:
1. Obtain an estimate of the linear predictor (LPi) using the rounded
points total:
LPi = β+B Points totalð Þ
(β: optimism-adjusted intercept [constant]; B: common factor).
2. Calculate the predicted likelihood from the inverse logit transforma-





The data set contained 905 544 dogs attending 886 VetCompass par-
ticipating practices in 2016. Search terms identified 10 141 dogs
where Cushing's syndrome was considered as a clinical diagnosis
which were manually examined to identify those that fulfilled the
criteria for inclusion in the study (n = 1625). Of these, the EHRs of
1000 (61.5%) randomly selected dogs were examined in detail and
extraction of clinical information was performed, identifying 419 cases
and 581 noncases. Animals with no recorded information regarding
clinical signs within the 2-week period of first suspicion were excluded
from the study, retaining 398/419 (95.0%) cases and 541/581 (93.1%)
noncases for analysis. The final disorders for noncases recorded within
the EHR were reported (Table 1). “Endocrine disorders” formed the
most common disorder category for noncases (n = 85, 15.7%) and
“unspecified hepatic disorder” was the most commonly recorded diag-
nosis (n = 56, 10.2%). The remaining 8516 dogs were categorized as
follows: Cushing's syndrome included as a differential diagnosis term in
the EHR but never investigated (n = 4756), confirmed Cushing's cases
diagnosed before 2016 (692), suspected iatrogenic Cushing's cases
(316), cases with a diagnosis suspected and investigated but never con-
firmed nor ruled out (1540), an incorrect use of the search terms
included (eg, Cushing's suture) (599), or Cushing's syndrome ruled out
before 2016 (613).
Median age at first suspicion of Cushing's cases was 10.8 years
(IQR 9.0-12.5; range 3.9-17.6) and 10.2 years (IQR 8.2-12.1; range
0.7-18.2) in noncases. Median bodyweight of cases was 11.4 kg (IQR
8.8-20.0; range 2.5-67.0) and 13.2 kg (IQR 9.3-25.1; range 1.7-80.5)
in noncases. Of cases, 212 (53.3%) were female compared to 275 (50.5%)
noncases. A higher proportion of cases were entire compared to noncases;
with 58/398 (14.6%) cases entire females compared to 39/541 (7.2%)
noncases and 53 (13.3%) cases were entire males compared to 61
(11.3%) noncases (P < .01). Crossbreeds made up 90 cases (22.6%)
and 114 noncases (21.1%). The most represented purebred was the
Jack Russell terrier (39 cases [9.8%]; 39 noncases [7.2%]), the Staf-
fordshire bull terrier (29 cases [7.3%] and 26 noncases [4.8%]), West
Highland white terrier (WHWT) (13 cases [3.3%]; 46 noncases
[8.5%]), and the Bichon Frise (32 cases [8.0%]; 24 noncases [4.4%])
(Table 2). Bodyweight was not included in the modeling process as it
was considered biologically collinear and therefore inherently related
with breed.28
Polydipsia was the most commonly recorded clinical sign, present
in 540/939 (57.5%) of the study population; 279/398 cases (70.1%)
and 261/541 noncases (48.2%) presented with this clinical sign. Poly-
uria was recorded in 429 (45.7%) of the population, 234/398 (60.2%)
of cases and 195/541 (36.0%) of noncases. When comparing dogs
presenting with both polydipsia and polyuria, these predictors appeared
to be collinear with few cases included in the discordant categories; poly-
dipsia without polyuria was present in 25 dogs (6.3%) and polyuria with-
out polydipsia was present in 136 dogs (25.2%). As the most frequently
recorded clinical sign, only polydipsia was included in the modeling pro-
cess. Vomiting and diarrhea did not appear statistically collinear therefore
were both included as potential predictors.
Continuous data for ALKP and USG were not included in analysis
as large proportions of the data were missing (>65%) and were not
deemed reliable for imputation. When comparing categorized ALKP
and ALT predictor variables, >75% of the data was concordant; there-
fore, these predictors were considered collinear and the most
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complete variable (ALKP) was included in analysis. Categorized vari-
ables of recorded raised ALKP, presence of proteinuria, or low USG
were included in model development. Missingness for veterinary
reported categorized clinicopathologic data was fairly high at around
50% (Table 2). Clinic ID was not included as a random effect in the
final model as the clinic attended accounted for only 1.5% of the vari-
ance observed in the data (LRT of rho P = .37, rho = .015).
The final model retained 10 predictors: breed, sex, age, polydipsia,
vomiting, potbelly/hepatomegaly, alopecia, pruritus, ALKP, and USG
(Table 3). No interactions or additional confounding factors were iden-
tified. Age was nonlinearly associated with the outcome and was
modeled as linear splines, with cutoffs categorizing age into 3 groups:
<7, 7 to <11, and ≥11 years.
Sex and breed were included into the model with entire females
and certain breeds (Border terriers and Bichon Frise) associated with
an increased predicted likelihood of Cushing's syndrome. Polydipsia,
potbelly, and alopecia were associated with an increased predicted
likelihood of Cushing's. The presence of a potbelly contributed the
greatest increased likelihood of receiving a diagnosis of Cushing's syn-
drome with an optimism-adjusted coefficient of 0.95 (β-coefficient = 1.11,
95% CI = 0.78-1.43, P < .001). The presence of vomiting and/or pruritus
was associated with a reduced predicted likelihood of Cushing's. The pres-
ence of a nonelevated ALKP and/or nondilute USG were associated with a
reduced predicted likelihood of Cushing's. A nonelevated ALKP had the
greatest contribution to reducing the likelihood of receiving a diagnosis of
Cushing's syndrome with an optimism-adjusted coefficient of −1.25
(β-coefficient = −1.46, 95% CI = −2.15 to −0.76, P < .001).
3.1 | Model performance
The calibration plot indicated good calibration with the confidence
intervals mostly overlapping the 45! line. Higher probability predic-
tions have wider confidence intervals and further deviation from the
45! line of perfect calibration, indicating more uncertainty (Figure 1).
The calibration estimates showed a c-slope of 0.86 indicating some
overfitting of the model and that predictions were moderately too
extreme (ie, low predictions were too low, high predictions were too
high) (Table 4). This was corrected for by applying the c-slope value as
the shrinkage factor to the model coefficients. CITL of 0.001 indicated
that the predictions were systematically well calibrated. Discrimina-
tion of the model was relatively good with an AUROC = 0.78 (95%
CI = 0.75-0.81) (Figure 2). Optimism-adjusted AUROC was estimated
to be 0.76. Brier score was 0.19 and Cragg and Uhler's R2 was 0.31
indicating moderate overall model performance.
3.2 | Prediction tool
A prediction tool from the final model was developed (Table 5). The
smallest significant optimism-adjusted coefficient in the model was
used as the common factor to standardize the coefficients and to
derive the tool's points, which was for “not recorded USG” (optimism-
TABLE 1 Diagnostic terms recorded in the electronic health




(%) Fine level diagnostic terms (n)
Cardiorespiratory 31 (5.73) Hypertension (10), bronchitis (7),
chronic heart disease (6),
pulmonary thromboembolism (3),
pericardial effusion (2), cor
pulmonale (1), brachycephalic
obstructive airway syndrome (1),
unspecified respiratory disorder (1)
Dermatological 67 (12.38) Unspecified dermatological disorder
(32), pyoderma (12), alopecia (8),
atopy/allergy (6), dermatitis (4),
flea allergy dermatitis (3), follicular
dysplasia (1), demodicosis (1)
Endocrine 85 (15.71) Hypothyroidism (34), insulin
resistance (24), diabetes mellitus




Gastrointestinal 40 (7.39) Gastroenteritis (34), inflammatory
bowel disease (3), parasitic disease
(2), megaesophagus (1)
Hepatobiliary 82 (15.16) Unspecified hepatic disorder (56),
hepatitis (12), cholangiohepatitis
(11), biliary mucocoele (3)
Infectious/
inflammatory
16 (2.96) Pancreatitis (12), sepsis (2), peritonitis
(1), tooth root abscess (1)
Miscellaneous 42 (7.76) Transient polydipsia (19), obesity
(16), medication adverse effects
(4), heat stroke (2),
hypertriglyceridemia (1)
Neoplastic 37 (6.84) Liver mass (9), unspecified mass (8),
adrenal mass (5), lymphoma (5),
pheochromocytoma (2), brain
tumor (2), anal sac carcinoma (1),
insulinoma (1), hemangiosarcoma
(1), mediastinal mass (1), oral
mass (1), transitional cell
carcinoma (1)
Neurological 20 (3.70) Unspecified neurological disorder
(11), psychogenic polydipsia (6),
cognitive dysfunction (2),
idiopathic epilepsy (1)
Ocular 10 (1.85) Sudden acquired retinal degeneration
syndrome (5), nonhealing corneal
ulcer (4), keratoconjunctivitis
sicca (1)
Orthopedic 22 (4.07) Arthritis (8), cruciate disease (7),
unspecified orthopedic disorder (7)
Renal 25 (4.62) Chronic kidney disease (18), protein-
losing nephropathy (4),
proteinuria (3)
Uro-genital 64 (11.83) Urinary tract infection (28),
incontinence (25), urolithiasis (6),
prostatic disease (3), unspecified
urinary disease (2)
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TABLE 2 Descriptive statistics and chi-squared associations with gaining a future diagnosis of Cushing's syndrome in dogs attending primary-
care veterinary practices in the United Kingdom (cases, n = 398; noncases: n = 541)
Variable Category Cases (%) Noncases (%) Chi-squared P value
Sex Female entire 58 (14.6) 39 (7.2) .001
Female neutered 154 (38.7) 236 (43.6)
Male entire 53 (13.3) 61 (11.3)
Male neutered 133 (33.4) 205 (37.9)
Breed Bichon frise 32 (8.0) 24 (4.4) <.001
Border terrier 23 (5.8) 11 (2.0)
Crossbreed 90 (22.6) 114 (21.1)
Jack Russell terrier 39 (9.8) 39 (7.2)
Labrador retriever 6 (1.5) 39 (7.2)
Other purebreed 140 (35.2) 198 (36.6)
Schnauzer 6 (1.5) 24 (4.4)
Staffordshire bull terrier 29 (7.3) 26 (4.8)
West highland white terrier 13 (3.3) 46 (8.5)
Yorkshire terrier 20 (5.0) 20 (3.7)
Age (y) <7 31 (7.8) 93 (17.2) <.001
7 to <11 180 (45.2) 229 (42.3)
≥11 187 (47.0) 219 (40.5)
Polydipsia Yes 279 (70.1) 261 (48.2) <.001
No 119 (29.9) 280 (51.8)
Polyuria Yes 234 (58.8) 195 (36.0) <.001
No 164 (41.2) 346 (64.0)
Polyphagia Yes 98 (24.6) 77 (14.2) <.001
No 300 (75.4) 464 (85.8)
Vomiting Yes 19 (4.8) 59 (10.9) .001
No 379 (95.2) 482 (89.1)
Diarrhea Yes 26 (6.5) 57 (10.5) .03
No 372 (93.5) 484 (89.5)
Potbelly/hepatomegaly Yes 197 (49.5) 116 (21.4) <.001
No 201 (50.5) 425 (78.6)
Thin/dry skin Yes 96 (24.1) 100 (18.5) .04
No 302 (75.9) 441 (81.5)
Alopecia Yes 118 (29.7) 81 (15.0) <.001
No 280 (70.3) 460 (85.0)
Pruritus Yes 15 (3.8) 45 (8.3) .005
No 383 (96.2) 496 (91.7)
Muscle wastage Yes 54 (13.6) 45 (8.32) .01
No 344 (86.4) 496 (91.7)
Lethargy Yes 73 (18.3) 112 (20.7) .37
No 325 (81.7) 429 (79.3)
Panting Yes 80 (20.1) 99 (18.3) .49
No 318 (79.9) 442 (81.7)
Neurological signs Yes 18 (4.5) 31 (5.7) .41
No 380 (95.5) 510 (94.3)
Insulin prescribed Yes 6 (1.5) 17 (3.1) .11
No 392 (98.5) 524 (96.9)
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adjusted coefficient = −0.38). The predicted likelihoods were calcu-
lated for each total score to develop a scoring system that covered a
range from −13 to 10 (Table 6). An individual dog scoring the lowest
possible score of −13 reflects a 0% predicted likelihood and the
highest possible score of 10 reflects a 96% predicted likelihood of
Cushing's syndrome.
4 | DISCUSSION
Our study outlines the development of a tool that predicts the diagno-
sis of Cushing's syndrome at the point of first suspicion, using EHRs
of dogs under primary-veterinary care in the United Kingdom. The
prediction tool has many benefits for veterinarians in primary-care
practice. Knowing the predicted likelihood of disease for an individual
dog through assimilation of the predictive clinical features of the dis-
ease could support decision-making for veterinarians in the practice
setting. Using this tool to selectively identify dogs with a higher likeli-
hood of disease before diagnostic testing with a LDDST or ACTH
stimulation test could improve the positive predictive value of such
tests. For example, using the tool for a 9-year-old, femaled-neutered,
crossbreed dog presenting only with polydipsia, ALKP is not elevated
and USG is not dilute the dog would gain a score of −3, indicating a
15% predicted likelihood of Cushing's syndrome. In this situation, the
attending veterinarian could consider it unlikely the dog has Cushing's
at the current time and further testing is not warranted. Additionally,
should pituitary-adrenal axis testing have been performed in this case
and a positive test obtained, the prediction tool result could highlight
that this result carries a low positive predictive value and should not
be taken as strong evidence in favor of a diagnosis of Cushing's syn-
drome. Obtaining a quantitative value of predicted disease likelihood
could also aid communication with owners during a consultation and
provide transparency of clinical decision-making.
The tool was developed from the prediction model which included
clinical signs, demographic factors, and some laboratory factors. The
model indicated good discrimination, with an AUROC = 0.78 (95%
CI = 0.75-0.81, optimism-adjusted AUROC = 0.76) and a good model
fit (Brier score = 0.19 and Cragg-Uhler's R2 = 0.31). The model largely
utilizes the clinical picture and performs well therefore highlighting that
gaining a good understanding of the clinical picture is vital.
The predictors assessed in our study were identified a priori
based on current knowledge of the disease using existing literature
and clinical expertise. The final model retained 10 predictors: breed,
sex, age, polydipsia, vomiting, potbelly/hepatomegaly, alopecia, pruri-
tus, ALKP, and USG. The presence of polydipsia and presence of a
potbelly contributed a higher predicted likelihood of disease within
the models and are commonly associated with Cushing's syndrome
in the literature.4,5,9 Dermatological changes are frequently observed in
dogs with Cushing's such as alopecia yet chronic glucocorticoid excess
in these dog also means that they are less likely to show signs of pruri-
tus.6,44 Sex was included in the model with the β-coefficients indicat-
ing female-entire dogs had the highest predicted likelihood. The
TABLE 2 (Continued)
Variable Category Cases (%) Noncases (%) Chi-squared P value
Thyroxine prescribed Yes 14 (3.5) 18 (3.3) .87
No 384 (96.5) 523 (96.7)
Cruciate disease in previous year Yes 11 (2.8) 7 (1.3) .10
No 387 (97.2) 534 (98.7)
Hospitalized in previous year Yes 55 (13.8) 81 (15.0) .62
No 343 (86.2) 460 (85.0)
Hypertensive medication prescribed Yes 3 (0.8) 8 (1.5) .31
No 395 (99.2) 533 (98.5)
Raised ALKP activity Yes 211 (53.0) 263 (48.6) .001
No 14 (3.5) 55 (10.2)
Unknown 173 (43.5) 223 (41.2)
Raised ALT activity Yes 163 (41.0) 179 (33.1) <.001
No 28 (7.0) 98 (18.1)
Unknown 207 (52.0) 264 (48.8)
Low USG Yes 117 (29.4) 110 (20.3) .001
No 49 (12.3) 101 (18.7)
Unknown 232 (58.3) 330 (61.0)
Proteinuria Yes 95 (23.9) 99 (18.3) .08
No 54 (13.6) 90 (16.6)
Unknown 249 (62.6) 356 (65.8)
Abbreviations: ALKP, alkaline phosphatase; ALT, aminotransferase; USG, urine specific gravity.
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reason for this observation is not known. A sex predisposition for
Cushing's syndrome has been investigated in studies examining this
causal relationship, with no clear association determined.2,16,45 How-
ever it must be reiterated that the primary aim of the current study
was to describe the predictive rather than the causal relationships
between the 2 groups being investigated.46 Our study includes different
comparative populations of dogs to previous studies that specifically looked
for causal relationships. Breeds such as the WHWT and Labrador retriever
had low predicted likelihood of Cushing's syndrome. These breeds
could have been overrepresented in the noncases because of predis-
position for other diseases presenting in a similar way to Cushing's.
For example, WHWTs are predisposed to skin disease and might have
had Cushing's investigated because of a dermatology work up.47
Raised ALKP has been frequently reported in dogs with a diagno-
sis of Cushing's syndrome.9,48 Additionally, a low USG has often been
recorded in the literature.49,50 ALKP and USG were included as
TABLE 3 Final predictors (including demographic, clinical signs, and clinicopathologic data) for a diagnosis of Cushing's syndrome after
multivariable logistic regression with bootstrap resampling, developed in dogs attending primary-care veterinary practices in the United Kingdom
(cases, n = 398; noncases: n = 541)
Predictor Category β-coefficient 95% Confidence interval P value (Wald) Optimism-adjusted β-coefficient
Neuter status Female-entire Baseline — — —
Female-neutered −.64 −1.17 to −0.12 .02 −.55
Male-entire −.34 −0.97 to 0.29 .29 −.29
Male-neutered −.60 −1.13 to −0.07 .03 −.52
Age (y) <7 Baseline — —
7 to <11 .64 0.13-1.15 .01 .55
≥11 .58 0.06-1.09 .03 .50
Polydipsia Yes .87 0.55-1.20 <.001 .75
No Baseline — —
Vomiting Yes −.76 −1.37 to −0.14 .02 −.65
No Baseline — —
Potbelly Yes 1.11 0.78-1.43 <.001 .95
No Baseline — —
Alopecia Yes .94 0.54-1.33 <.001 .80
No Baseline — —
Pruritus Yes −0.88 −1.56 to −0.20 .01 −.76
No Baseline — —
Breed Crossbreed Baseline — —
Bichon frise .68 0.01 to 1.35 .05 .58
Border terrier .61 −0.26 to 1.48 .17 .52
Jack Russell terrier .11 −0.47 to 0.69 .72 .09
Labrador retriever −1.37 −2.33 to −0.42 .005 −1.18
Other purebred −.04 −0.44 to 0.36 .84 −.04
Schnauzer −1.03 −2.06 to 0.01 .05 −.88
Staffordshire bull terrier .05 −0.63 to 0.73 .47 .04
West Highland white terrier −1.18 −1.91 to −0.45 .001 −1.02
Yorkshire terrier .09 −0.70 to 0.88 .82 .08
USG Dilute Baseline — — —
Not dilute −.85 −1.35 to −0.36 .001 −.73
Not recorded −.43 −0.82 to −0.06 .02 −.38
ALKP Elevated Baseline — — —
Not elevated −1.46 −2.15 to −0.76 <.001 −1.25
Not recorded −.16 −0.48 to 0.17 .34 −.13
Constant −.49 −1.24 to 0.25 .19 −.42
Note: β-coefficients were multiplied by the optimism-adjusted calibration-slope (0.86), estimated through bootstrap resampling to produce optimism-
adjusted coefficients.
Abbreviations: ALKP, alkaline phosphatase; USG, urine specific gravity.
8 SCHOFIELD ET AL.
categorical variables because of poor recording of specific values in
the EHRs. Availability of clinicopathologic data in our study was reli-
ant on the test having been performed within primary-care practice
and dependent on the system used by the veterinary practice to
record this information. Some tests performed at external laboratories
were not captured within VetCompass limiting the inclusion of this
data into the study. Additionally, variations in the laboratory equip-
ment used across practices might have introduced some noise into
the analysis of these factors. Further refinement to include additional
clinicopathologic data could provide future direction for this tool, such as
cholesterol and the stress leukogram, which were infrequently reported
in the EHRs and therefore not considered during data extraction in our
study. Multiple imputation has been shown to be unbiased for estimating
missing data up to 50% but can become unreliable for certain types of
missingness such as if data are “missing not at random” and associated
with the outcome of interest.30,31 It was elected not to impute this data
and instead these data were included within a “not recorded” category
for the ALKP and USG predictor variables rather than excluding these
variables or performing a complete case analysis.
Inappropriate prediction model development can lead to poor model
fit, giving falsely high and “optimistic” results which do not perform well in
novel data sets.18,19,51,52 Therefore, a necessary part of model development
is internal validation.18 Resampling techniques such as bootstrapping are
recommended, as opposed to split sampling methods, as they optimize data
usage to enable the model to be developed and internally validated on
the whole data set without losing any predictive power.33,53 Boot-
strap resampling estimates of performance indicate how the results
will generalize to an independent data set derived from the same pop-
ulation.33 The optimism-adjusted estimates, which account for poten-
tial overfitting and are less “optimistic,” showed good performance.
There was some overfitting of the model, indicated by the calibration
slope and the calibration plot indicated weaker calibration at the
higher probability predictions. The overfitting was accounted for by
shrinking the model coefficients therefore these adjusted estimates
F IGURE 1 Calibration plot of the final prediction model for a
diagnosis of Cushing's syndrome using multivariable logistic
regression with bootstrap resampling, developed in dogs attending
primary-care veterinary practices in the United Kingdom (cases,
n = 398; noncases: n = 541). The plot describes the mean observed
proportions of dogs with a diagnosis of Cushing's compared to the
mean predicted probabilities, by deciles of predictions. The 45! line
denotes perfect calibration
TABLE 4 Apparent performance
measures (performance of the bootstrap
samples), average optimism (the average
difference between the performance of
the bootstrap samples and the dogs not
included in the bootstrap samples) and
estimated optimism-adjusted
performance measures for the final







AUROC 0.78 0.02 0.76
CITL 0.00 −0.001 0.001
C-slope 1.00 0.14 0.86
Abbreviations: AUROC, area under the receiver operating characteristic curve; CITL, calibration-in-the-
large.
F IGURE 2 Receiver operating characteristic curve for the final
prediction model for a diagnosis of Cushing's syndrome using
multivariable logistic regression with bootstrap resampling, developed
in dogs attending primary-care veterinary practices in the
United Kingdom (cases, n = 398; noncases: n = 541)
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are likely representative of the tools performance in primary-care
practice. For models to be clinically useful, it is vital they are devel-
oped in a large, representative sample of the target population of inter-
est to optimize their predictive performance.17,18 The dogs included in
our study were selected from the largest research database of primary-
care EHRs in the United Kingdom, representing approximately 30% of
all UK veterinary practices.22 However, the tool could be applied to dif-
ferent prevalence populations when used in practice and could have
some impact on the predictive performance demonstrated in our study.
Future external validation (using an external, independent data set) of
the final prediction tool is required to assess its wider generalizability
and performance in clinical practice.17,39,54
The predictor variables included in our study represent the clinical
information typically used by veterinarians in practice to formulate a
perceived “pretest” probability of disease.55,56 The dogs included in
our study were required to have been suspected of having Cushing's
in the EHRs therefore were presumably perceived to have a greater
“pretest” probability of Cushing's by the attending veterinarian. The
tool could perform differently at varying thresholds of “pretest” prob-
abilities, used by differing veterinarians to consider the animal as a
TABLE 5 Prediction tool to calculate
the likelihood of a dog having Cushing's
syndrome using demographic, clinical
sign, and laboratory predictive factors,
developed in dogs attending primary-care
veterinary practices in the
United Kingdom (cases, n = 398;
noncases: n = 541)
Category Points Points scored
Dog demography




Current age (years) <7 0
≥7 1




West Highland white terrier −3













Urine specific gravity Dilute (≤ 1.020) 0
Not dilute (> 1.020) −2
Not recorded −1




Note: Regression β-coefficients from model B for each predictor variable were used as weights which
were multiplied by a common factor (“Not recorded” USG optimism-adjusted coefficient = 0.38) and
rounded to the nearest integer. To calculate the predicted likelihood of an individual dog having Cushing's
syndrome, add together the points that correspond to the category for each predictor and match to the
Table 6 below.
Abbreviations: ALKP, alkaline phosphatase; USG, urine specific gravity.
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potential Cushing's case. Clinical decision-making includes lots of
uncertainty as the perceived “pretest” probability formulated by the
veterinarian is subjective and likely varies between clinicians.55 The
tool developed in our study aimed to reduce some uncertainty sur-
rounding this clinical decision by helping to standardize the diagnostic
approach, without removing the clinical freedom of decision-making
by the veterinarian.
Adequate sample size is also important when developing a predic-
tion tool, with small samples leading to spurious associations from
overfitting of the data, producing coefficients that are too large and a
model that is too extreme.24,25 An a priori sample size estimation was
carried out to increase confidence that an adequate proportion of
cases were manually reviewed for inclusion in the study. Sample size
estimation using the EPV criteria of 10 cases per variable is frequently
cited in the literature; however, the reliability of this to ensure
adequate sample size has been questioned and other more reliable
methods are warranted.57
The use of strict inclusion criteria was used to increase confi-
dence and minimize misclassification between the identification of the
cases of Cushing's syndrome and the control population. There will
have been some dogs with Cushing's syndrome in the underlying
denominator population that did not meet the study definitions and
were excluded from analysis, highlighting the realities of primary-care
practice and the importance of using the intended population in the
development of a disease prediction tool.58 Additionally the categori-
zation of dogs as either a case or noncase were based on the diagno-
sis recorded within the EHR by the attending veterinarian; therefore,
this could have introduced some misclassification bias.
The developed tool makes a prediction of diagnosis early in the
trajectory of the disease. This was done to assist the diagnostic pro-
cess at the time point when veterinarians are making this clinical deci-
sion in practice and this was standardized for cases and noncases,
reducing the potential for bias in the identification of candidate pre-
dictors. Clinical signs present within a 2-week window from the point
of first suspicion were recorded to keep the dogs' clinical presentation
precise to that particular time frame and to reduce influence of bias
from the clinician with increasing or decreasing suspicion as disease
investigation progresses. When recording clinical sign data from the
EHRs, an assumption was made that if the clinical sign was present
within the 2-week window, it was likely to have been reported.59 It
was deemed unlikely that veterinarians would routinely record absent
clinical signs and therefore omission of a clinical sign was recorded as
“not present.” The requirement to have at least 1 clinical sign recorded
in the EHRs at the time of first suspicion was included to remove
cases that might have been poorly recorded. If at least 1 clinical sign
was recorded, it is assumed that this was the clinical sign of most con-
cern to the owner and/or the vet and therefore contributed to the
decision to undertake further investigations. In our study, polydipsia
was recorded in 70% of cases and polyuria was recorded in 59%. With
these 2 clinical signs inherently related and few dogs recorded with
discordant clinical signs, this could suggest that certain clinical signs
are more frequently and accurately recorded in the EHRs at primary-
care practices. Therefore, it is possible that some clinical signs were
present but remained unnoticed by the owner and not explicitly
recorded by the veterinarian during the consultation. These assump-
tions could have resulted in some misclassification of the clinical signs
status; however, any misclassification is likely similar for cases and
noncases so could bias the results to the null.
There are some limitations to our study. Some survival bias could
have been introduced by including incident cases between January
1, 2016 and June 1, 2018, with some dogs not surviving for the entire
study period and reducing their chance of being included in the study.
This potential bias is likely small over 2 years and likely similar for
cases and noncases. This study period was chosen to avoid excluding
dogs with a longer period of disease investigation and to reduce the
number of dogs where a diagnosis of Cushing's is neither confirmed
nor ruled out. Enhanced methods for case finding and selection would
be beneficial to extract greater volumes of information from such
TABLE 6 Points total and predicted likelihood of an individual
dog having Cushing's syndrome using demographic, clinical sign, and
laboratory predictive factors, developed in dogs attending primary-
care veterinary practices in the United Kingdom (cases, n = 398;
noncases: n = 541)
Points total
Predicted likelihood of Cushing's

























Note: The linear predictor (LPi) using the rounded points total was esti-
mated: LPi = β + B(Points total) (β: optimism-adjusted intercept [constant];
B: common factor). Then the predicted likelihood from the inverse logit
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large databases of EHRs. Novel, computationally intensive methods
such as natural language processing are being developed to facilitate
the identification of larger numbers of cases from the broader denom-
inator population.60 Additionally as data were retrospective and not
recorded primarily for research purposes, there could be variations in
how information was recorded by different veterinarians which could
introduce noise and reduce the performance of the score.
In conclusion, our study demonstrates the development of a diag-
nostic prediction tool for Cushing's syndrome in dogs at the point of
first suspicion. The tool provided takes a dog's demography, pre-
senting clinical signs and some routine laboratory results into consid-
eration and demonstrated a good predictive performance. The tool
can immediately be utilized in primary-care practice to directly aid
clinical decision-making and increase confidence in diagnosis. Devel-
opment of similar tools could prove beneficial for similarly hard to
diagnose conditions and it is hoped that this will ultimately result in a
positive impact on animal welfare.
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